Texas State University Prepares for Phase 2 Research on the Potential New Cancer and HIV Fighting ALKA-V6 Compound

Texas State University Prepares for Phase 2 Research on the Potential New
Cancer and HIV Fighting ALKA-V6 Compound

SAN MARCOS, Texas, Nov. 3 /PRNewswire/ -- Texas State University and Orizon
Research Institute announced the signing of an agreement today that will
permit University Researchers to continue efforts through in vivo testing to
further determine the potential and effectiveness of ALKA-V6, a compound which
has shown remarkable ability to kill cancer cells and inhibit the HIV virus in
laboratory experiments.

The research will evaluate the effects of ALKA-V6 on animal organisms, and
will be highly replicated with the goal of moving knowledge about the compound
toward eventual FDA approval.

Dr. Troy Chesnut, Managing Member of Orizon Research Institute, stated, "We
are excited to move our research from artificial laboratory systems to animal
organisms. These next 18 months of research should confirm previous studies
and provide more answers about this promising product."

The prelude from the Texas State University research proposal addresses the
reasons for optimism about the product. "ALKA-V6 is a modified value-added
silicon compound......This product has been imputed to have several health
benefits including anti-microbial activity, bone remodeling and joint health
promoting functions as well as chemotherapeutic benefits against cancer and
viral infections....In response to numerous testimonials/case studies,
empirical evidence and written personal and contractual statements about the
putative cancer reducing and alleviation in symptoms associated with several
viral diseases, we previously evaluated the anticancer and anti-HIV effects in
in vitro models. Our results largely corroborated the empirical observations
and many in vitro model systems. ALKA-V6 proved highly effective in
mitigating causative factors and conditions that promote cancer and HIV
infections. ALKA-V6 was extremely effective in preventing sodium azide
induced mutations, cancer cell survival, and cancer cell adhesion. In
addition, at very low concentrations, ALKA-V6 was also very effective in
promoting apoptosis, preventing free radical mediated DNA damage, activating
free radical neutralizing systems such as glutathione, superoxide dismutase
and catalase. ALKA-V6 was also very effective in its antiviral activities,
and at very low doses it was highly effective in inhibiting viral
transcription and replication. In addition, it was also very effective in
reducing viral cell attachment and ability of the virus to evade the immune
system.

In spite of these scientifically proven effects, most of these studies have
been conducted in in vitro systems.....

...Systematic studies need to be conducted in in vivo systems to decipher the
genetic and physiological mechanism of action, determine the effective dosages
for health promoting activity.....End point measurements as related to
modulation of genetic and metabolic pathways relevant to anti-metastatic and
anti-retroviral effects are imperative to completely establish the
functionality of ALKA-V6 in promoting homeostasis....

The results from this phase of testing may also result in scientific
acceptance of the product as an effective alternative/complementary tool for
management and prevention of different diseases."

Orizon Research Institute of Odessa, Texas is the international distributor of
ALKA V-6. Orizon remains committed to providing the ALKA-V6 compound to the
general public as an affordably priced nutritional supplement that can be
purchased directly from the company web site. The phase 1 ALKA-V6 research
study conducted at Texas State is also available on the Orizon Research web
site at www.orizonresearch.com.

CONTACT: Orizon Research, LLC, 1-877-367-7770, media@orizonresearch.com

SOURCE Orizon Research Institute

Orizon Research, LLC, 1-877-367-7770, media@orizonresearch.com